An expanded access record providing inolimomab in Steroid Resistant Acute Graft Versus Host Disease, sponsored by ElsaLys Biotech. Available at 1 site in France. Open to participants aged 28 Days and older. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by ElsaLys Biotech · Expanded access
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in a Long Term Follow Up study), the French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) so-called cohort ATU (cATU) for LEUKOTAC® (inolimomab) and approved the temporary use protocol .
This early access program has been granted to Leukotac (inolimomab) in adults and in children over 28 days of age, for treatment of acute cortico-resistant or cortico-dependent grades II-IV acute graft versus host disease (GvHD) according to the Glucksberg classification after allogeneic hematopoietic stem cell transplantation.
Despite improvements in allogeneic hematopoietic stem cell transplantation (allo-HSCT) settings, graft-versus-host disease (GvHD) remains a significant issue after transplantation and a major cause of non-relapse mortality. Acute GvHD (aGvHD) still develops in about 30% to 80% of patients, for which high dose corticosteroids can be initiated in those with grade ≥II. However, up to 50% of patients fail to obtain a satisfactory response with steroid treatment alone. Treatment of steroid-resistant (SR) aGvHD remains an unmet clinical need.
Inolimomab is an IgG1 mouse monoclonal antibody which specifically binds to the alpha chain of the human interleukin-2 receptor (CD25, IL-2R), a receptor expressed on the surface of the T cells in response in to antigenic stimulation.
Inolimomab efficacy in the treatment of corticosteroid-resistant graft-versus-host disease after allogenic hematopoietic stem cell transplant was assessed in a multicenter phase 3 randomized double-blind controlled study (INO-0107) versus Thymoglobulin® (anti-thymocyte globulin (ATG )).
Long term survival data were collected in the 43 surviving patients at the end of the phase 3 study INO-0107 (23 inolimomab; 20 ATG) and up to 104 months after discontinuation of treatment (median follow-up: 58.4 months). These long term follow-up data showed a statistically significant difference for survival with relative risk of death reduced by 43% in the inolimomab group (p=0.030). These data confirm the 1-year observations of the phase 3 study INO-0107 with a clear clinical benefit on survival statistically greater in patients receiving inolimomab.
Leukotac (inolimomab) is not approved yet for marketing in any region. This early access program has been granted to Leukotac (inolimomab) in adults and in children over 28 days of age, for treatment of acute cortico-resistant or cortico-dependent grades II-IV acute graft versus host disease (GvHD) according to the Glucksberg classification after allogeneic hematopoietic stem cell transplantation.
806 studies on the registry are indexed under Graft vs Host Disease; 138 are open to participants now.
Browse Graft vs Host Disease studies →ElsaLys Biotech is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase). Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28. In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28. Total duration of treatment is 28 ±2 days.
Also known as: Leukotac
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ElsaLys Biotech